SNMMI supports proposed expansion of cardiac PET coverage

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear Cardiology (ASNC) recently submitted comment to BlueCross BlueShield (BCBS) of Tennessee supporting its proposed expansion of cardiac PET coverage.

Currently, BCBS of Tennessee labels PET to determine absolute quantification of myocardial blood blow as “investigational,” according to the letter. However, authors of the Sept. 1 ASNC/SNMMI statement argue “the ability to routinely quantify myocardial blood flow in ml/min/gram is unique to PET, improves accuracy, risk stratification and patient selection for interventions.”

According to the letter, the non-coverage also goes against a joint position paper from the organizations which determined measuring flow absolutely, as opposed to comparatively, boosts the chances of defining patients with severe coronary artery disease (CAD).

SNMMI and ASNC also proposed changes to coverage for patients with “significant left ventricular dysfunction under consideration for revascularization” or “suspected cardiac sarcoid,” according to the letter.

Read the entire letter here.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.